ILLUMINA INC.

Company Snapshot

Founded: 1998
Entity Type: Public
Employees: 8,970
Region: Americas
Revenue: $4,372.0 Millions
Revenue Year: 2024
Segment: Core Illumina
Headquarter: California, U.S.
Key Geographics: Americas, Europe, Middle East, Africa, China, Asia-Pacific
Corporate Address: 5200 Illumina Way, San Diego, California, 92122 U.S. Tel. +1- 858-202-4500 www.illumina.com

Company Overview

Incorporated in April 1998, Illumina Inc. is a global life science company that develops and markets genetic analysis solutions for areas such as sequencing, genotyping, and expression. Illumina offers solutions for Multiomics, CNV, DNA methylation analysis, genome sequencing and gene expression profiling. The company operates through two major segments: Life Sciences and Diagnostics. Illumina’s Life Sciences unit offers products and services based on DNA sequencing, gene expression analysis, and real-time PCR to meet the demands of researchers in life science. The Diagnostics unit focuses on products and services in the area of molecular diagnostics, such as HiScan and iScan.

Illumina’s clientele includes genomic research institutes, clinical research organizations, governmental laboratories, and pharmaceutical and biotechnology companies. Illumina is currently headquartered in San Diego, California, and has sales offices and distributors located worldwide. The company operates under two reportable segments: Core Illumina and GRAIL.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

ILLUMINA INC. In Reports

Global DNA Read, Write, and Edit Market

BCC Research detailed report on DNA Read, Write and Edit Market includes global revenue ($ Million) for the base year 2024 and estimated data for the forecast period 2025 through 2030.

Noninvasive Cancer Diagnostics: Technologies and Global Markets

According to BCC Research detailed report on noninvasive cancer diagnostic market global revenue ($ Million) for the base year 2024, estimated data for 2025, and forecasts through 2026-2030.

Global Gene Fusion Testing Market

According to BCC Research detailed report on Global Gene Fusion Testing Market data from 2024, estimates from 2025, and projections of compound annual growth rates through 2030 (forecast period 2025–2030).

Company's Business Segments

  • Core Illumina : Research, clinical and applied markets, and genomic solutions
  • GRAIL : Healthcare company focused on early detection of multiple cancers.

Applications/End User Industries

  • Next-Generation Sequencing (NGS)
  • Cutting-Edge Array Scanners
  • In Vitro Diagnostic (IVD)
  • Reagents
  • Microarray Kits
  • Genotyping
  • Epigenetic Analysis
  • Vitro Diagnostic
  • Oncology Comprehensive
  • Sequencing Platform Comparison
  • Designstudio Software
  • Trusight Oncology
  • Basespace Sequence Hub
  • Dragen Secondary Analysis
  • Illumina Connected Analytics
  • Genomic Insights
  • Oncology Clinical Research
  • Laboratory Information Management System
  • Correlation Engine
  • Microarray Data Analysis
  • DNA Prep Portfolio
  • Life Sciences
AI Sentiment